Apparently at least one member of this WIPO UDRP panel did not appreciate his time being wasted with frivolous claims and less-than-truthful statements by the Complainant.
Read it here.
Archive for August, 2010
Berated by WIPO
Saturday, August 7th, 2010Big Brands = Little Tweeting
Wednesday, August 4th, 2010It seems that just because you may own a major brand, people are not necessarily tweeting about you or your brand. Of all Twitter traffic (i.e., “tweets”), only 10% are generated by the brand owners themselves. Of those, only 12% mention their brands. Check it out.
Thank you.
Tuesday, August 3rd, 2010We would like to thank CTCorsearch for including our blog on its blogroll at its own Trademark + Brands Blog. So, thank you, we appreciate it.
Sanofi-Aventis Launches New Cancer Treatment
Tuesday, August 3rd, 2010We congratulate our client, Sanofi-Aventis, on the launch of its new prostate cancer treatment, JEVTANA. The FDA approved JEVTANA (cabazitaxel) on June 17, 2010 for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen. Jevtana is administered intravenously.
Subsequently, Sanofi-Aventis launched JEVTANA in the United States on July 19, 2010. Jevtana in combination with prednisone is the only FDA approved regimen to significantly improve overall survival in patients previously treated with docetaxel-based chemotherapy regimen." Studies have shown that JEVTANA can increase survival by 30%.
We are proud to have played a role in helping Sanofi-Aventis bring this innovative and exciting treatment – and trademark – to market.